Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionGW&K Investment Management, LLC
Latest Disclosed Ownership140,458 shares
Latest Disclosed Value $ 4,173
GW&K Investment Management, LLC reports 0.51% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 13, 2026 - GW&K Investment Management, LLC filed a 13F-HR form disclosing ownership of 140,458 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $4,173,007 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 141,180 shares of Travere Therapeutics, Inc.. This represents a change in shares of -0.51% during the quarter. The current value of the position is $6,348,702 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 140,458 -722 -0.51 4 -20.00 0.0368
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 141,180 23,311 19.78 5 150.00 0.0466
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 141,180 5
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 141,180 5
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 141,180 5
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 141,180 5
2026-02-11 2025-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 141,180 5
2025-11-12 2025-09-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 117,869 -164,631 -58.28 3 -50.00 0.0249
2025-08-11 2025-06-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 282,500 -38,662 -12.04 4 -20.00 0.0374
2025-05-05 2025-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 321,162 -7,015 -2.14 6 0.00 0.0533
2025-02-05 2024-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 328,177 -169,748 -34.09 6 -16.67 0.0486
2024-11-07 2024-09-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 497,925 -12,201 -2.39 7 50.00 0.0596
2024-08-12 2024-06-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 510,126 182,347 55.63 4 100.00 0.0383
2024-05-08 2024-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 327,779 9,513 2.99 3 0.00 0.0223
2024-02-09 2023-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 318,266 -19,348 -5.73 3 -33.33 0.0267
2023-11-09 2023-09-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 337,614 -12,996 -3.71 3 -40.00 0.0303
2023-08-09 2023-06-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 350,610 48,856 16.19 5 -16.67 0.0511
2023-05-09 2023-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 301,754 60,020 24.83 7 20.00 0.0657
2023-02-10 2022-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 241,734 -2,104 -0.86 5 -99.92 0.0516
2022-11-09 2022-09-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 243,838 -2,688 -1.09 6,008 0.59 0.0663
2022-08-09 2022-06-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 246,526 -2,145 -0.86 5,973 -6.79 0.0644
2022-05-09 2022-03-31 13F/A-1 TRAVERE THERAPEUTICS COMMON 89422G107 248,671 -6,805 -2.66 6,408 -19.19 0.0466
2022-05-09 2022-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 248,671 -6,805 6,408 0.0571
2022-02-11 2021-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 255,476 -55,042 -17.73 7,930 5.31 0.0663
2021-11-10 2021-09-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 310,518 -4,231 -1.34 7,530 63.98 0.0673
2021-08-10 2021-06-30 13F TRAVERE THERAPEUTICS COMMON 89422G107 314,749 -6,485 -2.02 4,592 -42.75 0.0399
2021-05-11 2021-03-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 321,234 -3,066 -0.95 8,021 -9.25 0.0739
2021-02-05 2020-12-31 13F TRAVERE THERAPEUTICS COMMON 89422G107 324,300 -10,129 -3.03 8,839 43.16 0.0928
2020-11-10 2020-09-30 13F RETROPHIN COMMON 761299106 334,429 -5,650 -1.66 6,174 -11.05 0.0808
2020-08-06 2020-06-30 13F RETROPHIN COMMON 761299106 340,079 -8,186 -2.35 6,941 36.61 0.0975
2020-05-11 2020-03-31 13F RETROPHIN COMMON 761299106 348,265 157,879 82.93 5,081 87.98 0.0894
2020-02-10 2019-12-31 13F RETROPHIN COMMON 761299106 190,386 -14,103 -6.90 2,703 14.05 0.0361
2019-11-05 2019-09-30 13F RETROPHIN COMMON 761299106 204,489 60,363 41.88 2,370 -18.13 0.0333
2019-08-06 2019-06-30 13F RETROPHIN COMMON 761299106 144,126 -1,239 -0.85 2,895 -12.01 0.0439
2019-05-14 2019-03-31 13F RETROPHIN COMMON 761299106 145,365 -23,125 -13.72 3,290 -13.72 0.0530
2019-02-07 2018-12-31 13F RETROPHIN COMMON 761299106 168,490 -9,576 -5.38 3,813 -25.47 0.0752
2018-11-06 2018-09-30 13F RETROPHIN COMMON 761299106 178,066 -4,550 -2.49 5,116 2.77 0.0823
2018-08-07 2018-06-30 13F RETROPHIN COMMON 761299106 182,616 -9,537 -4.96 4,978 15.85 0.0815
2018-05-08 2018-03-31 13F RETROPHIN COMMON 761299106 192,153 1,608 0.84 4,297 7.02 0.0726
2018-01-19 2017-12-31 13F RETROPHIN COMMON 761299106 190,545 55,130 40.71 4,015 19.14 0.0686
2017-10-11 2017-09-30 13F RETROPHIN COMMON 761299106 135,415 -1,704 -1.24 3,370 26.74 0.0562
2017-07-11 2017-06-30 13F RETROPHIN COMMON 761299106 137,119 -2,476 -1.77 2,659 3.18 0.0459
2017-04-10 2017-03-31 13F RETROPHIN COMMON 761299106 139,595 -1,346 -0.96 2,577 -3.41 0.0485
2017-01-17 2016-12-31 13F RETROPHIN COMMON 761299106 140,941 -19,920 -12.38 2,668 -25.89 0.0519
2016-10-18 2016-09-30 13F RETROPHIN COMMON 761299106 160,861 64,874 67.59 3,600 110.53 0.0676
2016-07-26 2016-06-30 13F/A-1 RETROPHIN COMMON 761299106 95,987 10,465 12.24 1,710 46.40 0.0353
2016-07-11 2016-06-30 13F RETROPHIN COMMON 761299106 95,987 1,710
2016-04-19 2016-03-31 13F RETROPHIN COMMON 761299106 85,522 40,097 88.27 1,168 33.33 0.0259
2016-01-15 2015-12-31 13F RETROPHIN COMMON 761299106 45,425 -1,180 -2.53 876 -7.20 0.0206
2015-10-08 2015-09-30 13F RETROPHIN COMMON 761299106 46,605 975 2.14 944 -37.61 0.0225
2015-07-08 2015-06-30 13F RETROPHIN COMMON 761299106 45,630 45,630 1,513 0.0344
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.